Latest news

• Sage gets final US clearance for postpartum depression drug Zulresso

  The DEA clearance means Zulresso will reach the first patients in late June. ... range of meaningful support resources to women with PPD and their families to help navigate the Zulresso treatment journey.

• Sage’s postpartum depression treatment Zulresso gains US approval

  First approval of its kind. The FDA has approved Sage Therapeutics’ treatment for postpartum depression, Zulresso (brexanolone). ... Today’s approval of Zulresso represents a game-changing approach to treating PPD,” said Dr.

• Sage raises $575m ahead of FDA review date for Zulresso

  of a possible US launch for Zulresso, says the company’s SEC prospectus for the fundraising. ... efficacy in tackling symptoms – just like Zulresso – but is less prone to causing side effects including loss of consciousness.